Faron Pharmaceuticals' EIC Accelerator funded project MAGIF “Faron leading the way in macrophage guided immunotherapy” is focused on progressing the MATINS study and related business activities.
The ongoing phase I/II MATINS clinical trial is investigating the tolerability, safety and efficacy of Clevegen, the Company's wholly-owned novel precision cancer immunotherapy targeting Clever-1 positive tumour associated macrophages (TAM), in selected metastatic or inoperable solid tumours.
- Invested amount
EUR 11 935 462
- Press Release